Department of Health Policy, London School of Economics and Political Science, London, England, UK; School of Public Health, Imperial College London, St Mary's Campus, Paddington, England, UK.
Department of Health Policy, London School of Economics and Political Science, London, England, UK.
Value Health. 2021 Aug;24(8):1213-1222. doi: 10.1016/j.jval.2021.01.013. Epub 2021 May 18.
To systematically review the literature on the unit cost and cost-effectiveness of malaria control.
Ten databases and gray literature sources were searched to identify evidence relevant to the period 2005 to 2018. Studies with primary financial or economic cost data from malaria endemic countries that took a provider, provider and household, or societal perspective were included.
We identified 103 costing studies. The majority of studies focused on individual rather than combined interventions, notably insecticide-treated bed nets and treatment, and commonly took a provider perspective. A third of all studies took place in 3 countries. The median provider economic cost of protecting 1 person per year ranged from $1.18 to $5.70 with vector control and from $0.53 to $5.97 with chemoprevention. The median provider economic cost per case diagnosed with rapid diagnostic tests was $6.06 and per case treated $9.31 or $89.93 depending on clinical severity. Other interventions did not share enough similarities to be summarized. Cost drivers were rarely reported. Cost-effectiveness of malaria control was reiterated, but care in methodological and reporting standards is required to enhance data transferability.
Important information that can support resource allocation was reviewed. Given the variability in methods and reporting, global efforts to follow existing standards are required for the evidence to be most useful outside their study context, supplemented by guidance on options for transferring existing data across settings.
系统回顾疟疾控制的单位成本和成本效益的文献。
检索了 10 个数据库和灰色文献来源，以确定与 2005 年至 2018 年期间相关的证据。纳入了来自疟疾流行国家的具有主要财务或经济成本数据的研究，这些研究从提供者、提供者和家庭或社会角度出发。
我们确定了 103 项成本研究。大多数研究侧重于个体干预措施而非联合干预措施，特别是驱虫蚊帐和治疗，而且通常采用提供者的视角。所有研究中有三分之一发生在 3 个国家。每年保护 1 人的提供者经济成本从采用病媒控制的 1.18 美元到 5.70 美元不等，从采用化学预防的 0.53 美元到 5.97 美元不等。使用快速诊断检测诊断出 1 例病例的提供者经济成本中位数为 6.06 美元，每例治疗病例的费用为 9.31 美元或 89.93 美元，具体取决于临床严重程度。其他干预措施没有足够的相似之处可以进行总结。成本驱动因素很少有报道。疟疾控制的成本效益再次得到强调，但需要注意方法学和报告标准，以增强数据的可转移性。
审查了可以支持资源分配的重要信息。鉴于方法和报告的差异，需要在全球范围内努力遵循现有标准，以便在研究背景之外最有效地利用证据，并补充关于在不同环境中转移现有数据的选项的指导。
